REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
05/24/2025
Back to search
Official data from USPTO
BAXALTA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
BAXALTA
ST13
US500000079165660Class
5, 9, 10, 16, 38, 41, 44
Filing
79165660
Registration
4961987
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
53
Latest update
05/25/2025
Trademark type
Word
Nice classes
5, 9, 10, 16, 38, 41, 44
Filing date
02/25/2015
Registration date
05/24/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/01/2022
Last transaction
05/25/2025
Responsible office
United States Patent and Trademark Office
Status code
707
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
Bannockburn, IL
Examiner
CARLSON, KRISTIN
Law office
L50
Holders and representatives
Holders
B. I. (pessoa física)
Baxter International Inc.
Representatives
A. Tally Eitan Gornitzky & Co
Technical classification
Nice Classes
Class 5Class 9Class 10Class 16Class 38Class 41Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparationssubstances and products for the treatment of blood diseases and disordersimmuno deficiency disorderscancer; pharmaceuticals for the treatment of blood diseases and disordersimmuno deficiency disorderscancer; pharmaceutical preparationsproteinase inhibitors in the nature of alpha-1 proteinase inhibitors; pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersall containing immune globulin infusion (human) and recombinant human hyaluronidase; reconstitution assembly sold containing vials prefilled with pharmaceutical preparations for the treatment of blood diseases and disorders; normal serum albumin (human) solution for intravenous administration; immunoglobulin for parenteralintramuscular and intravenous administration to humans; antihemophilic factor for intravenous administration in humans; antihemophilic factor recombinant; pharmaceutical preparationschemotherapeutic agents
Class 9
Computer software for use in the inputting of patient information for transmission to health care professionals; computer software for use in calculating and tailoring the optimal dosage for patients; computer application software for recording and analyzing patient information; computer application softwaresoftware for tracking and managing patients' medication and wellness; computer software for tracking and managing pharmaceutical infusions and physical conditions of patients with bleeding disorders; computer software program for mobile phonestabletshand held devices and computers for tracking patient information and providing educational information in the field of hemophilia treatment optionsdesigned for patients and health care professionals; downloadable electronic publicationsnewslettersarticlesbrochuresbookletswhite papers and presentations in the field of pharmaceuticalshealth carehealth insurancemedical informationbleeding conditionshemophiliahematologyimmunologyoncology and patient care
Class 10
Medical devicesdevices for reconstituting dried pharmaceuticals; medical apparatus and instrumentsmedical infusion set for subcutaneous delivery of pharmaceuticals; medical apparatus for the preparation and parental infusion of pharmaceutical preparations
Class 16
Printed publications for teachingbrochuresbookletstraining manuals and teaching materialsnewsletters and white papers in the fields of pharmaceuticalshealth carehealth insurancemedical informationbleeding conditionshemophiliahematologyimmunologyoncology and patient care; printed publicationsbrochuresbookletstraining manuals and teaching materialsnewsletters and white papers in the fields of pharmaceuticalshealth carehealth insurancemedical informationbleeding conditionshemophiliahematologyimmunologyoncology and patient care; publicationsprinted instructional and educational guides featuring information about bleeding conditions
Class 38
Provision of access to computer databases containing medical information related to hematologicalimmunological and oncological diseasesdisorders and treatment
Class 41
Education and training servicesproviding classesseminarsconferenceslectures and workshops in the fields of pharmaceuticalshealth carehealth insurancemedical informationbleeding disorders or conditionshemophiliahematologyimmunologyoncology and patient care; education servicesproviding non-downloadable electronic publications in the nature of newsletters and white papers in the field of hemophilia; provision of information for training and teaching relating to pharmaceuticalshealth carehealth insurancemedical informationbleeding disorders or conditionshemophiliahematologyimmunologyoncology and patient care; provision of non-downloadable electronic publicationsnewslettersarticlesbrochures and booklets in the field of pharmaceuticalshealth carehealth insurancemedical informationbleeding disorders or conditionshemophiliahematologyimmunologyoncology and patient care
Class 44
Medical services and health care; health care servicesproviding care for human health; medical serviceshuman blood component collection services; medical servicesblood purification; medical servicesproviding medical information in the field of oncologyimmunology and hematology via a website; providing an online database for identifying the optimal dosage of medications for patients; medical servicesproviding free trial prescription service programs for pharmaceutical preparations for the treatment of blood disorders
Publications
History of USPTO decisions and trademark events.
53 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/28/2025
RNWL
INTERNATIONAL REGISTRATION RENEWED
12/12/2024
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
10/15/2023
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
08/30/2023
INPC
INVALIDATION PROCESSED
08/30/2023
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
08/01/2023
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
12/01/2022
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
12/01/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/07/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/22/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/21/2022
ES71
TEAS SECTION 71 RECEIVED
05/23/2022
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
05/24/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/08/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/15/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/15/2016
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/25/2016
FIMP
FINAL DISPOSITION PROCESSED
08/25/2016
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/24/2016
R.PR
REGISTERED-PRINCIPAL REGISTER
05/24/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/08/2016
PUBO
PUBLISHED FOR OPPOSITION
03/08/2016
GPNX
NOTIFICATION PROCESSED BY IB
03/04/2016
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/17/2016
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/17/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/17/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/03/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/27/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/15/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/14/2016
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
01/14/2016
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/11/2016
GNFR
FINAL REFUSAL E-MAILED
01/11/2016
CNFR
FINAL REFUSAL WRITTEN
01/11/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/19/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/19/2015
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/19/2015
ALIE
ASSIGNED TO LIE
12/18/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/04/2015
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/19/2015
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/19/2015
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/01/2015
CHLD
CHANGE OF OWNER RECEIVED FROM IB
07/31/2015
RFNT
REFUSAL PROCESSED BY IB
06/27/2015
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/09/2015
RFRR
REFUSAL PROCESSED BY MPU
06/09/2015
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/06/2015
CNRT
NON-FINAL ACTION WRITTEN
06/05/2015
MAFR
APPLICATION FILING RECEIPT MAILED
06/05/2015
DOCK
ASSIGNED TO EXAMINER
06/02/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/01/2015
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/30/2015
Continuous trademark protection
Get notified about every new filing that threatens BAXALTA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.